Also thank you for informing me that Oncology Pharma is responsible for raising the money needed to fund those TWO (2) INDs and I might add they have a limited amount of time to do that. Do you know what the deadline date is for that? In my experience of CROs they typically don't perform raising capital to fund INDs although they're know to assist with resource funding.
Again ALL the points you made are spot on, excellent summary that brings everything to light.
Would you care to enlighten me further about what exactly is the role Canary plays if acquired by Regen? Are these people clinical research pharmacologists and/or biochemists?? Do they have expertise in taking candidate drug IPs to Turn Key IND's ready for entrance into clinical trials?? I'm not 100% certain what their exact role is.
Lastly, what applicable benefit did the consultant BRG bring to the table that benefited Regen? What exactly did they do for Regen that helped in the company's market directives?
News 
Market Data 
Discover 
AI
